Clinical trials
catalyst calendar across sponsors →Studies where SLDB is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
5 interventional · 1 observational
Held by 11 tracked-famous managers (CITADEL ADVISORS LLC, Point72 Asset Management, L.P., D. E. Shaw & Co., Inc., Balyasny Asset Management L.P., SUSQUEHANNA INTERNATIONAL GROUP, LLP, +6 more) · FINRA short interest 16.2 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)NCT07160634Change From Baseline in Time to Rise (TTR) from Supine Velocity (rise/s) at Day 540Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: SGT-003, Placebo | Duchenne Muscular Dystrophy | 80 | Jan 2029 | ≤ 896 d | 2026-08-13 |
| A Study of SGT-212 Gene Therapy in Friedreich's AtaxiaNCT07180355Incidence and Severity of Treatment Emergent Adverse Events (TEAEs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: SGT-212 | Friedreich's Ataxia (FA) | 10 | 2028-03-21 | in 580 d | 2026-08-17 |
| A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)NCT07148089Number of Participants with Treatment-Emergent Adverse Event (TEAEs)s through Day 360Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: SGT-501 | Catecholaminergic Polymorphic Ventricular Tachycardia | 18 | Jun 2027 | ≤ 315 d | 2026-08-10 |
| A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)NCT06138639Incidence of treatment-emergent adverse events (AEs)Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Genetic: SGT-003 | Duchenne Muscular Dystrophy | 60 | 2027-05-06 | in 260 d | 2026-07-08 |
| Microdystrophin Gene Transfer Study in Adolescents and Children With DMDNCT03368742Number of Participants with Treatment Emergent Adverse Events (TEAEs)Non-randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Genetic: SGT-001 | Duchenne Muscular Dystrophy | 12 | 2026-10-15 | in 57 d | 2026-08-10 |
| Evaluation of Home Based Assessments on Participants With DMDNCT05657938observationalWearable sensor device compliance | — | Completed | Device: Wearable Device · Other: Duchenne Video Assessment (DVA) | Duchenne Muscular Dystrophy | 17 | 2023-04-04actual | — | 2023-08-14 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19